Neurocrine Biosciences Inc. Common Stock (NBIX): valor razonable

Tesis ACCE

Neurocrine Biosciences develops and sells neuroscience drugs, with its core franchise built on Ingrezza, a treatment for tardive dyskinesia, and Crenessity, a therapy for congenital adrenal hyperplasia. The company has a durable edge in CNS (central nervous system) commercialization, where specialist prescriber relationships and long-dated patent protection make share hard for competitors to take. Revenue growth of 39.5% is the headline, and the near-term driver is continued uptake of Crenessity alongside Ingrezza's established base, with operating margin at 22.2% and gross margin at 64.5% indicating the mix is shifting toward high-margin product sales. At a trailing P/E of 19.8 against a forward P/E of 11.2, the market is pricing in a steep earnings ramp, so the question for the deeper work is whether that ramp is as durable as the forward multiple implies. With a 22.1% ROE and a 13.7B market cap, the name is worth a closer look on the durability of Crenessity uptake and Ingrezza's exposure to competition and pricing pressure.